Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960].
| Status | Suspended |
| Decision | Selected |
| Process | TA |
| ID number | 3733 |
Project Team
| Project lead | Shonagh D'Sylva |
Email enquiries
- If you have any queries please email TAteam2@nice.org.uk
Stakeholders
| Companies sponsors | AbbVie (upadacitinib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | British Association of Dermatologists |
| British Society for Allergy & Clinical Immunology | |
| Royal College of Physicians | |
| Professional groups | Allergy UK |
| National Eczema Society | |
| Comparator companies | Accord (azathioprine, methotrexate, mycophenolate mofetil) – not participating |
| Advanz Pharma (methotrexate) – not participating | |
| Aspen (azathioprine) – not participating | |
| Cipla (methotrexate) – not participating | |
| Dexcel-Pharma Limited (ciclosporin) – not participating | |
| Ennogen (alitretion, azathioprine) – not participating | |
| GlaxoSmithKline (alitretion) – not participating | |
| Hospira (methotrexate) – not participating | |
| Medac (methotrexate) – not participating | |
| Mylan (azathioprine, ciclosporin, mycophenolate mofetil) – not participating | |
| Nordic Pharma (methotrexate) – not participating | |
| Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil) | |
| Orion Pharma (methotrexate) – not participating | |
| Pfizer (methotrexate) | |
| Roche (mycophenolate mofetil) – not participating | |
| Rosemont Pharmaceuticals (methotrexate) – not participating | |
| Sandoz (methotrexate, mycophenolate mofetil) – not participating | |
| Sanofi (dupilumab) | |
| Santen (ciclosporin) – not participating | |
| Teva (mycophenolate mofetil) – not participating | |
| Therakind (methotrexate) – not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2021 | Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 05 August 2021 | Suspended. Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 21 July 2021 | Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022 . |
| 21 July 2021 | We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022. |
| 10 December 2020 | Invitation to participate |
| 10 December 2020 | In progress. Final scope issued |
| 16 July 2020 - 13 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual